FDA label
What is Vyndaqel used for?
Vyndaqel contains tafamidis. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Vyndaqel?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Vyndaqel, capsule, liquid filled
Indications and Usage, quoted from the label by Pfizer Laboratories Div Pfizer Inc (NDA211996). Cross-references to other label sections are left out.
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Source: DailyMed label, set id 1b4121ee-a733-4456-a917-be2603477839, version 15, effective May 12, 2026. NDC 0069-1975, one of 1 listing for this product.
Questions
What is Vyndaqel used for?
The FDA label says: “VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.”
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.